Markets

Why BeiGene Stock Jumped Today

What happened

Shares of BeiGene (NASDAQ: BGNE) were jumping 10.6% higher as of 3:09 p.m. EDT on Tuesday. The nice gain came after Bloomberg reported that Hillhouse Capital plans to buy $1 billion worth of the Chinese biotech's shares. On July 12 BeiGene announced the pricing of a stock offering of more than 145.8 million shares valued at $2.08 billion.

So what

Stock offerings dilute the value of existing shares. As a result, they often cause share prices to tumble. In BeiGene's case, though, there was one unusual characteristic about its offering that caused the biotech stock to rise: the sheer size of the transaction.

Arrow and bar chart trending up over a man's palm

Image source: Getty Images.

BeiGene's stock offering is "the largest equity offering ever by a biotech company," according to Bloomberg. Hillhouse Capital's $1 billion investment serves as an anchor for the deal. Others have also already stepped up to buy shares, including Amgen, which already owns over 20% of BeiGene.

Perhaps most importantly, the eagerness of Hillhouse Capital and others to invest large amounts in BeiGene underscores the overall attractiveness of the biotech's potential. BeiGene currently markets Brukinsa in treating mantle cell lymphoma and is evaluating the drug in several clinical studies targeting other indications. Elzonris is approved in China for treating classical Hodgkin's lymphoma and urothelial carcinoma. BeiGene also sells cancer drugs Abraxane and Revlimid in China under a license from Bristol Myers Squibb.

Now what

Look for more potential catalysts on the way for BeiGene. The company expects to announce results from a study of zanubrutinib (Brukinsa) with bendamustine plus rituximab in treating chronic lymphocytic leukemia or small lymphocytic lymphoma in the second half of 2020. It also awaits regulatory approvals for Brukinsa in Europe and for tislelizumab in China. 

10 stocks we like better than BeiGene
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and BeiGene wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

 

*Stock Advisor returns as of June 2, 2020

 

Keith Speights owns shares of Bristol Myers Squibb. The Motley Fool owns shares of and recommends Bristol Myers Squibb. The Motley Fool recommends Amgen. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

BGNE BMY AMGN

Latest Markets Videos

    The Motley Fool

    Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

    Learn More